Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate…
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a ‘Study May…